{"name":"BiondVax Pharmaceuticals ltd.","slug":"biondvax-pharmaceuticals-ltd","ticker":"","exchange":"","domain":"","description":"BiondVax Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on developing innovative vaccines and adjuvants. The company's lead candidate, M-001, is in Phase 3 trials, while several other candidates are in earlier stages of development.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":1311000,"revenueGrowth":99.2,"grossMargin":-202.3,"rdSpend":2369000,"netIncome":-8307000,"cash":1661000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Adjuvanted Multimeric-001 250mcg","genericName":"Adjuvanted Multimeric-001 250mcg","slug":"adjuvanted-multimeric-001-250mcg","indication":"Other","status":"phase_1"},{"name":"Adjuvanted PBS","genericName":"Adjuvanted PBS","slug":"adjuvanted-pbs","indication":"Seasonal influenza prevention","status":"phase_2"},{"name":"M-001","genericName":"M-001","slug":"m-001","indication":"Influenza prevention (universal/broad-spectrum protection)","status":"phase_3"}]}],"pipeline":[{"name":"Adjuvanted Multimeric-001 250mcg","genericName":"Adjuvanted Multimeric-001 250mcg","slug":"adjuvanted-multimeric-001-250mcg","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Adjuvanted PBS","genericName":"Adjuvanted PBS","slug":"adjuvanted-pbs","phase":"phase_2","mechanism":"Adjuvanted PBS is a polyepitope peptide-based vaccine that stimulates broad immune responses against multiple influenza strains by combining conserved viral peptides with an adjuvant.","indications":["Seasonal influenza prevention"],"catalyst":""},{"name":"M-001","genericName":"M-001","slug":"m-001","phase":"phase_3","mechanism":"M-001 is a multivalent recombinant influenza vaccine designed to stimulate broad immune responses against multiple influenza strains.","indications":["Influenza prevention (universal/broad-spectrum protection)"],"catalyst":""}],"recentEvents":[],"realNews":[{"date":"2026-04-01","type":"earnings","source":"SEC EDGAR","summary":"20-F filed with SEC: ANNUAL REPORT","headline":"Annual Report (20-F) Filed","sentiment":"neutral"},{"date":"2026-03-23","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: REPORT OF FOREIGN PRIVATE ISSUER","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-03-19","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: REPORT OF FOREIGN PRIVATE ISSUER","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-02-25","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: REPORT OF FOREIGN PRIVATE ISSUER","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-02-17","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: REPORT OF FOREIGN PRIVATE ISSUER","headline":"6-K Filing","sentiment":"neutral"},{"date":"2025-12-23","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: REPORT OF FOREIGN PRIVATE ISSUER","headline":"6-K Filing","sentiment":"neutral"},{"date":"2025-12-02","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: REPORT OF FOREIGN PRIVATE ISSUER","headline":"6-K Filing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAJBVV95cUxQOXJDc1FSYmV2bU84N21JeGg5Nm9EVjNTWHF5WjN4XzEzVzhuZUNxSENzdld1V2VuN3RxZ3hNcVhDNUMxazVuYWNDeGVoOEFuOE1uOGd4RVF0X05xMHo4TGxhYUdXRXljZ0NhSlpDTTRha0puRzd1U1hPZFBvTmdiWWwxajIzOWdsbXZ5eTMxcGIzQ3dmWlJTc1VJc3JsVm9PV0gxYkw5WnRGcnVhdFgyQ3g3Z3pESGZ0dGhmcmd1ZDdVMlBiWEFmWHctRDNZYVl3RERlOGRkQ0RBMEdhNk5RVE50OHQ1V3JIVF9nLWFlVi0zQUpnamJzbWQ1QmhuSjZOVlpiQURrU21LM1FGa1dKWTlWVGFqYnROV3FpeVhzTzVPM1hPeGJNRTdWNGFSZEVFUUpVLUpvZkwyZzRMUEd3YzB5Sk4?oc=5","date":"2025-12-01","type":"regulatory","source":"Business Wire","summary":"Human Vaccines Strategic Business Analysis Report 2025: Emergence of New Pathogens Drives Demand for Novel Vaccines - Global Forecast to 2030 - ResearchAndMarkets.com - Business Wire","headline":"Human Vaccines Strategic Business Analysis Report 2025: Emergence of New Pathogens Drives Demand for Novel Vaccines - Gl","sentiment":"neutral"},{"date":"2025-11-13","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: REPORT OF FOREIGN PRIVATE ISSUER","headline":"6-K Filing","sentiment":"neutral"},{"date":"2025-11-13","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: REPORT OF FOREIGN PRIVATE ISSUER","headline":"6-K Filing","sentiment":"neutral"},{"date":"2025-10-06","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: REPORT OF FOREIGN PRIVATE ISSUER","headline":"6-K Filing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxQRmtRT251c041dThFQldiREtXTW9LeVNDcUNxaWpLaGViQXczczdRRXA0VTVRcGt4YnFJTk9WaE1KR3cyUjZBblJnREJHdFgyVV83TlBicEhSUUhkMlE3N1dKMXpISzRZR285MWxmQmE5Z2dtVDVDZXJZNF9oM3phbnBaT0NubGtsVTI3Rmw3YjdPWHFGTFBXbDVHaWx0cWZLOXdtRnptVXUyeWhpVGZuNVFEUkdQd3pFQWJBemJvZw?oc=5","date":"2023-09-14","type":"pipeline","source":"Fierce Pharma","summary":"After Kenvue spinoff, J&J says it's 'uniting' Janssen and medtech segments under one brand - Fierce Pharma","headline":"After Kenvue spinoff, J&J says it's 'uniting' Janssen and medtech segments under one brand","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQWDVtb3JYT0hnbDdwYU1RdXpYcXE4bVVhZGFJaUYzcnBxcHBISXVPNVowZmtYSGxiNWt6YjRaQXEtWnNHOGpwNjBzWDhjZVNRQWswTjNKaVNqSm13LVNKUVc0VzczNU1hZk4yWTVaTWZHNDN2Wlk0dDBmSEFwYWVWbmdVWGNZY0NrWWFMclNQazJseUpPVnFnS1NqWGM5X3JQM2xweFM5dVpsTDE2eFVLNXJVQ2ZGUEMzMHRJ?oc=5","date":"2023-09-06","type":"pipeline","source":"Fierce Pharma","summary":"BiondVax Pharmaceuticals hits branding reset to become Scinai Immunotherapeutics amid a troubled year - Fierce Pharma","headline":"BiondVax Pharmaceuticals hits branding reset to become Scinai Immunotherapeutics amid a troubled year","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxPRXFKYzdtenZiLTVVLXlPTmRTZW95b2NxSDhJWU5OdVF3Tnhsd1RLWGRTSlNDYnFkYVhndlV2ZGVTcng3Wi1BR3IxdGoxWmVUMDhkMWYwZWhWRnNrWk5zM3MzU3p6WHBuc01lV1V0ckxNNjRCNVJhQWFYeFAyS3d3WnZNT1hKdTJsbWxRRjZkdGxQRnc3SGxfTHE1S3EwZXpyR3hyUWVWanllU0lG?oc=5","date":"2023-09-06","type":"pipeline","source":"Contract Pharma","summary":"BiondVax Pharmaceuticals Rebrands as Scinai Immunotherapeutics - Contract Pharma","headline":"BiondVax Pharmaceuticals Rebrands as Scinai Immunotherapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxQLUZPcm1IZEdZMjE0ZGJVVTZZazN5OVZyZngwMHNXcEI0SG9SR3VNR1VyOEt6eWlyLUozT3FBVWZaa1ZGMlh0THZFem1Gb0JsRFF2eFhXRFFuYU92RDFwNHlHd0NwXy1JeWtsRmwyQklkMnRnWDg4R2NrejBMclJieWRsUkdOb015azQtd3cxd1FxZmxN?oc=5","date":"2023-09-06","type":"pipeline","source":"Yahoo Finance","summary":"BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological Therapeutics - Yahoo Finance","headline":"BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel In","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_1":1,"phase_2":1,"phase_3":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":1311000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":1311000,"period":"2025-12-31"},{"value":658000,"period":"2024-12-31"}],"grossProfit":-2652000,"grossProfitHistory":[],"rdSpend":2369000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-8307000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":1661000,"cashHistory":[],"totalAssets":11626000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}